Pancreatic Cancer Research

ResearcherInstitute of Science TokyoActive in the last 2 years

Hiroaki Ono

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9230-5714; OpenAlex author ID A5068785193. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 11

  1. PAD2-Mediated Histone Citrullination Drives Tumor Progression by Enhancing Cell Proliferation and Modifying the Microenvironment in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-24-1095↗
  2. Identification of a novel target of SETD1A histone methyltransferase and the clinical significance in pancreatic cancer. Co-author DOI 10.1111/cas.15615↗
  3. RRM1 is mediated by histone acetylation through gemcitabine resistance and contributes to invasiveness and ECM remodeling in pancreatic cancer. Co-author DOI 10.3892/ijo.2023.5499↗
  4. C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer. Co-author DOI 10.1038/s41598-021-89530-8↗
  5. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection. Co-author DOI 10.1371/journal.pone.0249885↗
  6. Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells. First author DOI 10.1371/journal.pone.0252917↗
  7. Successful conversion surgery of distal pancreatectomy with celiac axis resection (DP-CAR) with double arterial reconstruction using saphenous vein grafting fo… Co-author DOI 10.1186/s40792-020-01082-7↗
  8. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality. Co-author DOI 10.1002/ijc.32072↗
  9. P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer. Co-author DOI 10.18632/oncotarget.10117↗
  10. PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-15-0034↗
  11. PTK6 promotes cancer migration and invasion in pancreatic cancer cells dependent on ERK signaling. Co-author DOI 10.1371/journal.pone.0096060↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoru Tanabe · 8 shared papers, 2019–2025 · strength 1.05
  2. Shinji Tanaka · 7 shared papers, 2020–2025 · strength 0.97
  3. Kosuke Ogawa · 7 shared papers, 2019–2023 · strength 0.86
  4. Daisuke Ban · 6 shared papers, 2019–2025 · strength 0.74
  5. Shuichi Watanabe · 6 shared papers, 2019–2023 · strength 0.73
  6. Tomotaka Kato · 3 shared papers, 2021–2023 · strength 0.40
  7. Yoshiki Murase · 3 shared papers, 2020–2023 · strength 0.37
  8. Hiromichi Ito · 4 shared papers, 2014–2021 · strength 0.36
  9. Toshiro Ogura · 3 shared papers, 2019–2021 · strength 0.32
  10. Daisuke Asano · 2 shared papers, 2023 · strength 0.31
  11. Aya Maekawa · 2 shared papers, 2020–2021 · strength 0.22
  12. Kentaro Umemura · 1 shared paper, 2025 · strength 0.19
  13. Yosuke Igarashi · 1 shared paper, 2025 · strength 0.19
  14. Yoshiaki Tanji · 1 shared paper, 2025 · strength 0.19
  15. Yuji Soejima · 1 shared paper, 2025 · strength 0.19
  16. Ayano Kabashima · 1 shared paper, 2023 · strength 0.16
  17. Takeshi Ishii · 1 shared paper, 2023 · strength 0.16
  18. Toshitaka Sugawara · 1 shared paper, 2021 · strength 0.12
  19. Shinji Tanaka · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.